Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 3(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02990806Phase 3Completed

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

Role: lead

NCT01927263Phase 3Completed

A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis

Role: lead

NCT01931189Phase 1Completed

Pharmacokinetics Study of NI-071

Role: lead

NCT01567358Phase 1Completed

Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis

Role: lead

All 4 trials loaded